At SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, we are driven to develop life-changing medicines for patients with severe rare diseases and cancer. Since our launch in 2017, we have worked to identify and advance promising science, beginning with our licensed clinical therapies from Pfizer Inc. We pioneer efficient pathways for drug development, leveraging shared-value partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the full potential of science for patients. Two of our therapies will be entering potentially pivotal studies in the first half of 2019: nirogacestat, a gamma secretase inhibitor for the treatment of desmoid tumors, and PD-0325901, a MEK 1/2 inhibitor for neurofibromatosis type 1 patients with plexiform neurofibromas. PD-0325901 also holds promise as the backbone for combination therapies to treat metastatic solid tumors. At SpringWorks Therapeutics, we ignite the power of promising science to unleash new possibilities for patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/02/19 | $125,000,000 | Series B |
ArrowMark Partners Bain Capital BVF Partners GlaxoSmithKline HBM Healthcare Investments Laurion Capital Management OrbiMed Advisors Perceptive Advisors  Pfizer Strategic Investments Group Samsara BioCapital Surveyor Capital Tavistock Group | undisclosed |
